13F Holdings
中文EN

JBIO Jade Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1798749 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-29.9%
TTM EPS YoY44.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-51.4%
ROA-47.4%
ROIC (approx.)-55.4%
Asset turnover—

Leverage & solvency

Liabilities / assets6.4%
Debt / equity0.00x
Current ratio16.03x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$93.12M$53.19M$64.22M$38.62M$14.99M
SG&A expense$20.42M$21.41M$17.19M$14.62M$8.04M
Operating income-$113.54M-$74.60M-$81.41M-$53.24M-$23.02M
Pretax income-$127.35M-$69.57M-$75.47M-$51.49M-$22.96M
Income tax$58,000$55,000$56,000$25,000$3,000
Net income-$127.41M-$69.63M-$75.52M-$51.51M-$22.96M
EBITDA-$113.52M-$74.31M-$81.31M-$53.17M-$23.01M
EPS (basic)-3.19-2.44-2.87-2.10-1.87
EPS (diluted)-3.19-2.44-2.87-2.10-1.87
Weighted avg. shares (diluted)31.36M28.58M26.33M24.47M12.29M
Balance sheet
Cash & equivalents$88.44M$69.39M$23.49M$22.40M$54.20M
Short-term investments$247.72M$0$98.95M$106.82M$113.18M
Current assets$348.82M$69.65M$124.23M$131.50M$174.33M
PP&E, net$170,000$0$288,000$242,000$186,000
Total assets$349.78M$72.80M$127.42M$135.30M$175.36M
Current liabilities$16.54M$12.00M$17.64M$7.78M$2.55M
Total liabilities$17.26M$119.60M$17.96M$8.56M$2.94M
Shareholders' equity$332.52M-$46.80M$109.46M$126.74M$172.42M
Shares outstanding49.32M3.67M27.76M24.72M24.41M
Cash flow statement
Operating cash flow-$94.69M-$71.20M-$56.78M-$39.12M-$27.40M
Capital expenditure$196,000—$142,000$195,000$181,000
Free cash flow-$94.89M—-$56.92M-$39.32M-$27.58M
Investing cash flow-$247.01M$56.03M$11.88M$6.93M-$113.43M
Financing cash flow$360.77M$25.43M$46.00M$396,000$190.46M
Depreciation & amortization$26,000$282,000$96,000$68,000$15,000
Stock-based compensation$20.01M$11.31M$11.91M$5.48M$2.04M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.